Paradigm Biopharmaceuticals Limited

DB:P86 Stock Report

Market Cap: €43.4m

Paradigm Biopharmaceuticals Future Growth

Future criteria checks 0/6

Paradigm Biopharmaceuticals is forecast to grow earnings at 8.8% per annum. EPS is expected to grow by 56.9% per annum.

Key information

8.8%

Earnings growth rate

56.9%

EPS growth rate

Biotechs earnings growth34.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated08 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:P86 - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2024N/A-59-66-66N/A
3/31/20240-64-72-72N/A
12/31/20230-69-78-78N/A
9/30/20230-60-62-62N/A
6/30/2023N/A-52-45-45N/A
3/31/20230-48-39-39N/A
12/31/20220-44-33-33N/A
9/30/20220-42-33-33N/A
6/30/20220-39-32-32N/A
3/31/20220-40-32-32N/A
12/31/20210-41-32-32N/A
9/30/20210-37-34-34N/A
6/30/20210-34-35-35N/A
3/31/20210-31-29-29N/A
12/31/2020-1-28-24-23N/A
9/30/20200-20-17-17N/A
6/30/2020N/A-12-10-10N/A
3/31/20202-14-10-10N/A
12/31/20194-16-10-10N/A
9/30/20193-16-8-8N/A
6/30/20193-16-6-6N/A
3/31/20193-11-7-7N/A
12/31/20183-7-7-7N/A
9/30/20183-7-6-6N/A
6/30/20183-6-6-6N/A
3/31/20182-6N/A-4N/A
12/31/20172-5N/A-3N/A
9/30/20172-5N/A-4N/A
6/30/20172-4N/A-4N/A
3/31/20172-4N/A-5N/A
12/31/20161-4N/A-6N/A
9/30/20161-4N/A-5N/A
6/30/20161-3N/A-4N/A
3/31/20161-3N/A-3N/A
12/31/20150-2N/A-1N/A
9/30/20150-2N/A-1N/A
6/30/2015N/A-2N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: P86 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: P86 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: P86 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if P86's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if P86's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if P86's Return on Equity is forecast to be high in 3 years time


Discover growth companies